Robust isolation of malignant plasma cells in multiple myeloma-Reference-Cited by-同舟云学术

Robust isolation of malignant plasma cells in multiple myeloma

Published:2014-02-27 Issue:9 Volume:123 Page:1336-1340
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Frigyesi Ildikó¹,Adolfsson Jörgen¹,Ali Mina¹,Kronborg Christophersen Mikael¹,Johnsson Ellinor¹,Turesson Ingemar²,Gullberg Urban¹,Hansson Markus¹²,Nilsson Björn¹³⁴

Affiliation:

1. Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Sweden;

2. Hematology Clinic, Skåne University Hospital, Lund, Sweden;

3. Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Lund, Sweden; and

4. Broad Institute, Cambridge, MA

Abstract

Key Points Molecular characterization of myeloma requires isolation of malignant plasma cells, which is currently hampered by the instability of CD138. We identified CD319 and CD269 as robust replacements for CD138, facilitating molecular diagnostics in myeloma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/9/1336/1378673/1336.pdf

Reference25 articles.

1. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.;Bergsagel;Blood,2013

2. Initial genome sequencing and analysis of multiple myeloma.;Chapman;Nature,2011

3. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.;Nilsson;Br J Haematol,2003

4. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.;Lin;Am J Clin Pathol,2004

5. Conventional diagnostics in multiple myeloma.;San Miguel;Eur J Cancer,2006

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma;International Journal of Laboratory Hematology;2024-09-12

2. Enhancing mutation detection in multiple myeloma with an error-corrected ultra-sensitive NGS assay without plasma cell enrichment;Cancer Cell International;2024-08-12

3. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial;The Lancet Haematology;2024-07

4. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy;Frontiers in Bioscience-Landmark;2024-06-17

5. Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model;Blood Advances;2024-04-11